Publication: Genome-Wide Association Study of Metamizole-Induced Agranulocytosis in European Populations.
Loading...
Identifiers
Date
2020-10-29
Authors
Cismaru, Anca Liliana
Rudin, Deborah
Ibañez, Luisa
Liakoni, Evangelia
Bonadies, Nicolas
Kreutz, Reinhold
Carvajal, Alfonso
Lucena, Maria Isabel
Martin, Javier
Sancho Ponce, Esther
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Agranulocytosis is a rare yet severe idiosyncratic adverse drug reaction to metamizole, an analgesic widely used in countries such as Switzerland and Germany. Notably, an underlying mechanism has not yet been fully elucidated and no predictive factors are known to identify at-risk patients. With the aim to identify genetic susceptibility variants to metamizole-induced agranulocytosis (MIA) and neutropenia (MIN), we conducted a retrospective multi-center collaboration including cases and controls from three European populations. Association analyses were performed using genome-wide genotyping data from a Swiss cohort (45 cases, 191 controls) followed by replication in two independent European cohorts (41 cases, 273 controls) and a joint discovery meta-analysis. No genome-wide significant associations (p
Description
MeSH Terms
Adult
Aged
Aged, 80 and over
Agranulocytosis
Biomarkers, Pharmacological
Case-Control Studies
Dipyrone
Europe
Female
Genetic Predisposition to Disease
Genome-Wide Association Study
Germany
Humans
Male
Middle Aged
Neutropenia
Retrospective Studies
Switzerland
Aged
Aged, 80 and over
Agranulocytosis
Biomarkers, Pharmacological
Case-Control Studies
Dipyrone
Europe
Female
Genetic Predisposition to Disease
Genome-Wide Association Study
Germany
Humans
Male
Middle Aged
Neutropenia
Retrospective Studies
Switzerland
DeCS Terms
CIE Terms
Keywords
dipyrone, drug-induced agranulocytosis, genome-wide association study, metamizole, pharmacogenetics